Page 8 - Sanket Koul

M3M to deploy ₹14,500 crore to fund construction of 45 mn sqft portfolio

M3M India plans to deploy ₹14,500 crore to accelerate construction of over 45 million sq ft, funded through internal accruals and working capital

As generics wave builds up, Novo Nordisk slashes Ozempic, Wegovy prices

Drugmaker says it will not undertake similar steps for its oral semaglutide brand Rybelsus

Signature Global, RMZ complete ₹1,293 cr deal to fund Gurugram project

RMZ acquires 50 per cent stake in subsidiary GCL; partners form joint venture to develop large mixed-use commercial project on Gurugram's Southern Peripheral Road corridor

Corona Remedies acquires Wokadine from DRL, enters iodine market

Acquisition of Wokadine marks Corona Remedies' entry into India's Rs 648 crore povidone iodine segment, strengthening its specialty portfolio and distribution reach

CDSCO asks states to maintain vigil on unlicensed IVF device sales

Regulator flags rise in unlicensed IVF device sales as smaller fertility centres turn to cheaper alternatives amid pricing pressures and lack of awareness

Golden Growth Fund aims to liquidate two projects, buy land in FY27

Real estate AIF plans to exit two independent floor projects and acquire land parcels in South and Lutyens' Delhi, amid rising luxury housing demand and price appreciation

Dubai on the edge: Indian HNIs don't loosen grip on trophy assets

Luxury real estate mkt holds firm; investors selective about buying

Table Space leases 1.45 lakh sq feet commercial space in Gurugram

According to transaction documents accessed by Propstack, the company will pay rent for a chargeable area of 145,181 square feet, putting the monthly rent rate at ₹185 per square foot

Taxiing to take off, Jewar airport likely to drive land value surge

Infrastructure push, industrial growth and relative affordability are expected to drive residential demand and investor interest across Jewar, Noida and Greater Noida markets

Office leasing up 15% on-year in Jan to Mar 2026 on occupier demand

Office leasing in India's top cities rose 15% in Q1 CY26, driven by strong occupier demand and GCC expansion, with flex leasing also gaining a larger share

NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise

Drug pricing regulator permits marginal MRP increase for NLEM medicines in line with wholesale price index, offering relief to manufacturers facing higher costs

Govt to intensify surveillance, audits against unauthorised GLP-1 sales

Online pharmacies, drug wholesalers under scanner; non-compliance may lead penalties, license cancellations

Blackstone-backed ASK Property Fund exits Mahagun's project for ₹650 cr

ASK Property Fund has exited Mahagun's Noida project with Rs 650 crore, earning a 21 per cent IRR, as the stalled development sees revival following NCLT relief

Domestic medtech lobby seeks govt support as key input costs rise 50%

Domestic medical device makers seek government support as input costs surge up to 50 per cent amid West Asia disruptions, flagging supply chain stress and rising logistics costs

Somerset Indus closes $288 mn fund, eyes larger healthcare investments

Somerset Indus has closed its third fund at $288 million, exceeding its target, and plans larger investments across healthcare, medtech, and insurance-linked sectors

CDSCO flags 4 spurious drugs, 194 fail quality tests in February 2026

CDSCO flagged four drugs as spurious and 194 as not of standard quality in February 2026, including widely used medicines, as part of routine surveillance

Semaglutide prices crash up to 90% as 15+ generics launch in two days

Off-patent GLP-1 therapy drives 70-90% price drop with generics flooding in

NCLT allows withdrawal of insolvency process against ATS Knightsbridge

ATS eyes delivery of project in 18 to 24 months, reset in core NCR luxury market

Dr Reddy's enters semaglutide market, launches diabetes generic drug

Drugmaker expects to receive regulatory approval for weightloss sema generic in a few months

Semaglutide generics may fuel rush for cosmetic weight loss, warn doctors

As semaglutide goes off patent, doctors warn of misuse by non-obese individuals amid rising demand driven by social media and lower-cost generics